Methods of determining susceptibility of tumors to tyrosine kinase inhibitors

US9140689B2 · kind B2 · utility

Assignees

• The Translational Genomics Research Institute · US
• Queensland University of Technology · AU

Inventors

• Sara Byron · Phoenix, US
• Pamela Pollock · Forsayth, AU

Key dates

• Filing date: Mar 14, 2011
• Grant date: Sep 22, 2015
• Expiry date: Jun 18, 2034

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR2 variants, which are linked to drug resistance. The disclosure further provides methods of diagnosis and theranosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.